Setback for India's polio-eradication program

29 May 2019
vaccinebig

Several doses of an oral polio vaccine made by a government-owned firm in India have failed quality tests.

In what is being termed a major setback to India’s polio eradication program, the Central Drugs Laboratory in Kasauli, Himachal Pradesh, declared 16 batches (30,000 vials) manufactured by Bibcol (Bharat Immunological and Biologicals Corporation Limited) as 'substandard'.

The public sector undertaking supplies vaccines to the government’s polio eradication program. Approximately 90 million doses of the polio vaccine are required for a follow-up program slated for June.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical